Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.87
CRIS's Cash to Debt is ranked higher than
64% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. CRIS: 1.87 )
CRIS' s 10-Year Cash to Debt Range
Min: 1.68   Max: No Debt
Current: 1.87

Equity to Asset 0.53
CRIS's Equity to Asset is ranked higher than
65% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CRIS: 0.53 )
CRIS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.95
Current: 0.53

0.12
0.95
F-Score: 3
Z-Score: -11.68
M-Score: 0.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -71.91
CRIS's Operating margin (%) is ranked higher than
71% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. CRIS: -71.91 )
CRIS' s 10-Year Operating margin (%) Range
Min: -6639.83   Max: -35.24
Current: -71.91

-6639.83
-35.24
Net-margin (%) -91.32
CRIS's Net-margin (%) is ranked higher than
70% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. CRIS: -91.32 )
CRIS' s 10-Year Net-margin (%) Range
Min: -35140.52   Max: -27.72
Current: -91.32

-35140.52
-27.72
ROE (%) -33.91
CRIS's ROE (%) is ranked higher than
70% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. CRIS: -33.91 )
CRIS' s 10-Year ROE (%) Range
Min: -364.5   Max: -11.29
Current: -33.91

-364.5
-11.29
ROA (%) -17.96
CRIS's ROA (%) is ranked higher than
74% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. CRIS: -17.96 )
CRIS' s 10-Year ROA (%) Range
Min: -331.19   Max: -10.23
Current: -17.96

-331.19
-10.23
ROC (Joel Greenblatt) (%) -1742.64
CRIS's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. CRIS: -1742.64 )
CRIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4184.27   Max: -206.43
Current: -1742.64

-4184.27
-206.43
Revenue Growth (%) -5.00
CRIS's Revenue Growth (%) is ranked higher than
72% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CRIS: -5.00 )
CRIS' s 10-Year Revenue Growth (%) Range
Min: -40.5   Max: 72.9
Current: -5

-40.5
72.9
EBITDA Growth (%) 26.00
CRIS's EBITDA Growth (%) is ranked higher than
93% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CRIS: 26.00 )
CRIS' s 10-Year EBITDA Growth (%) Range
Min: -49.4   Max: 26
Current: 26

-49.4
26
EPS Growth (%) 35.70
CRIS's EPS Growth (%) is ranked higher than
95% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. CRIS: 35.70 )
CRIS' s 10-Year EPS Growth (%) Range
Min: -74.5   Max: 35.7
Current: 35.7

-74.5
35.7
» CRIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CRIS Guru Trades in Q3 2013

Jean-Marie Eveillard 17,427,693 sh (+2.22%)
» More
Q4 2013

CRIS Guru Trades in Q4 2013

Jean-Marie Eveillard 17,889,009 sh (+2.65%)
» More
Q1 2014

CRIS Guru Trades in Q1 2014

Jean-Marie Eveillard 17,935,951 sh (+0.26%)
» More
Q2 2014

CRIS Guru Trades in Q2 2014

George Soros 44,000 sh (New)
Jim Simons 511,600 sh (New)
Jean-Marie Eveillard 19,468,451 sh (+8.54%)
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.63 - $2.97 $ 1.51-26%44000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.28
CRIS's P/B is ranked higher than
82% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. CRIS: 3.28 )
CRIS' s 10-Year P/B Range
Min: 1.03   Max: 10.95
Current: 3.28

1.03
10.95
P/S 8.39
CRIS's P/S is ranked higher than
82% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. CRIS: 8.39 )
CRIS' s 10-Year P/S Range
Min: 2.5   Max: 84.6
Current: 8.39

2.5
84.6
EV-to-EBIT -9.63
CRIS's EV-to-EBIT is ranked higher than
62% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CRIS: -9.63 )
CRIS' s 10-Year EV-to-EBIT Range
Min: 88.5   Max: 1121.1
Current: -9.63

88.5
1121.1
Current Ratio 6.15
CRIS's Current Ratio is ranked higher than
82% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. CRIS: 6.15 )
CRIS' s 10-Year Current Ratio Range
Min: 2.89   Max: 25.89
Current: 6.15

2.89
25.89
Quick Ratio 6.15
CRIS's Quick Ratio is ranked higher than
83% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. CRIS: 6.15 )
CRIS' s 10-Year Quick Ratio Range
Min: 2.89   Max: 25.89
Current: 6.15

2.89
25.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.04
CRIS's Price/Net Cash is ranked higher than
90% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. CRIS: 6.04 )
CRIS' s 10-Year Price/Net Cash Range
Min: 1.78   Max: 21.58
Current: 6.04

1.78
21.58
Price/Net Current Asset Value 5.21
CRIS's Price/Net Current Asset Value is ranked higher than
91% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. CRIS: 5.21 )
CRIS' s 10-Year Price/Net Current Asset Value Range
Min: 1.78   Max: 20.04
Current: 5.21

1.78
20.04
Price/Tangible Book 4.31
CRIS's Price/Tangible Book is ranked higher than
83% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. CRIS: 4.31 )
CRIS' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 15.25
Current: 4.31

1.63
15.25
Price/Median PS Value 0.59
CRIS's Price/Median PS Value is ranked higher than
94% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CRIS: 0.59 )
CRIS' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 24.31
Current: 0.59

0.09
24.31
Earnings Yield (Greenblatt) 0.70
CRIS's Earnings Yield (Greenblatt) is ranked higher than
53% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. CRIS: 0.70 )
CRIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.1
Current: 0.7

0.1
1.1
Forward Rate of Return (Yacktman) -12.93
CRIS's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. CRIS: -12.93 )
CRIS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -32.2   Max: -15.7
Current: -12.93

-32.2
-15.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CUS.Germany
Curis, Inc., was organized as a Delaware corporation in February 2000. It began its operations in July 2000 upon the completion of the merger of Creative BioMolecules, Inc., Ontogeny, Inc. and Reprogenesis, Inc. The Company is a drug discovery and development company that is committed to leveraging its signaling pathway drug technologies in seeking to develop next generation targeted cancer therapies. The Company's advanced program is its Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly-owned member of the Roche Group. The drug candidate being developed under this program is Erivedge, a first-in-class orally-administered small molecule Hedgehog pathway inhibitor, which is also referred to as vismodegib, GDC-0449 and RG3616. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. Genentech is also conducting a separate phase II clinical trial of Erivedge in patients with operable nodular basal cell carcinoma, which is a less severe form of the disease and accounts for a significant percentage of the approximately two million BCCs diagnosed annually in the United States. In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the U.S. National Cancer Institute. In addition to the ongoing clinical trials that Genentech and Roche are conducting, Genentech and the National Cancer Institute, entered into a collaborative relationship that allows the NCI to study GDC-0449 in additional potential cancer indications. The Company's competitors include large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms, that are developing cancer therapies in the same indications as it is.
» More Articles for CRIS

Headlines

Articles On GuruFocus.com
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 14 2013 
Weekly CFO Sells Highlight: USB, GNC, WWWW, GWRE, CRIS, CSL Apr 30 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 
Curis Inc. Reports Operating Results (10-Q) Aug 03 2010 
cooldecency99 note on CRIS May 01 2010 
Jean-Marie Eveillard Buys More Curis Inc. Aug 11 2009 
Curis Reports Second Quarter 2009 Financial Results and Provides Pipeline Update Jul 30 2009 
Curis Inc. Reports Operating Results (10-Q) May 06 2009 
Curis Reports Fourth Quarter and Year-End 2008 Financial Results Feb 10 2009 

More From Other Websites
Taseko Mines Announces Friendly Acquisition of Curis Resources Sep 08 2014
Curis Resources Announces Acquisition by Taseko Mines Sep 08 2014
Curis Resources Files Shareholder Meeting Materials Sep 02 2014
Curis to Present at Upcoming Investor Conferences Aug 27 2014
CURIS INC Financials Aug 19 2014
Ligand Gains on Q2 Earnings Beat, Increases Guidance Aug 07 2014
CURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
Q2 2014 Curis Inc Earnings Release - Before Market Open Aug 07 2014
Curis Reports Second Quarter 2014 Financial Results Aug 07 2014
Is a Surprise Coming for Curis (CRIS) This Earnings Season? Aug 01 2014
Curis to Release Second Quarter 2014 Financial Results and Hold Conference Call on August 7, 2014 Jul 31 2014
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% Jul 17 2014
CVS Caremark to Expand with Navarro Discount Pharmacy Buyout Jul 15 2014
Will Curis (CRIS) Crush Estimates at Its Next Earnings Report? Jul 10 2014
Curis (CRIS) Soars: Stock Adds 11.4% in Session Jul 01 2014
Curis and Roche File Label Expansion for Erivedge Jun 25 2014
Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase 2 Study of... Jun 23 2014
Curis updates agreement with Red Kite Jun 12 2014
Curis Re-Initiates Dosing for CUDC-427 Jun 06 2014
CURIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jun 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK